The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose escalation clinical trial

BACKGROUND: Dysregulated cyclin-dependent kinases (CDKs) are important to the growth of some sarcomas. Flavopiridol is a pan-CDK inhibitor that has been shown to potentiate chemotherapy. As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and perfor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Luke, Jason J., D’Adamo, David R., Dickson, Mark A., Keohan, Mary Louise, Carvajal, Richard D., Maki, Robert G., de Stanchina, Elisa, Musi, Elgilda, Singer, Samuel, Schwartz, Gary K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3343204/
https://ncbi.nlm.nih.gov/pubmed/22374332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3203
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados